Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer

Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer
Seattle, Washington (PRWEB) April 16, 2015 Dana-Farber Cancer Institute and its Belfer Institute for Applied Cancer Science and Resolution Bioscience, Inc. today announced the successful completion of a collaborative agreement to co-develop a novel, blood-based, clinic ready, Next Generation Sequencing (NGS) assay for non-small cell lung cancer (NSCLC). The collaboration is the first to demonstrate ...

New Device Makes Early Lung Cancer Detection Possible

New Device Makes Early Lung Cancer Detection Possible
Bloomington, Minnesota (PRWEB) December 02, 2014 November was Lung Cancer Awareness Month and healthcare advocates like the American Lung Association used the event to press for additional research, improved early detection, more effective screening and better treatment. Responding to these needs, one American medical device maker has developed a non-invasive screening technology that could ...

Frontier Pharma – NSCLC – Identifying And Commercializing First-In-Class Innovation In Non-Small-Cell Lung Carcinoma – Available online at MarketResearchReports.Biz

Frontier Pharma - NSCLC - Identifying And Commercializing First-In-Class Innovation In Non-Small-Cell Lung Carcinoma - Available online at MarketResearchReports.Biz
ALBANY, New York (PRWEB) December 01, 2014 Marketresearchreports.biz has included a new market research report titled “Frontier Pharma – NSCLC – Identifying and Commercializing First-in-Class Innovation in Non-Small-Cell Lung Carcinoma” to its extensive collection of research reports. To Read Complete Report with Toc: http://www.marketresearchreports.biz/analysis/228987 According to the report, growth in the Non-Small Cell ...